Gossamer Bio GOSS 深 沪
等待开盘 12-24 09:30:00 美东时间
3.285
-0.485
-12.86%
华盛通- 最 高3.77
- 今 开3.75
- 成交量 566.54万股
- 最 低 3.21
- 昨 收 3.77
- 总市值 7.59亿
- 52周最高 3.87
- 市盈率 静 --
- 换手率 2.45%
- 52周最低 0.76
- 委 比 56.89%
- 总股本 2.31亿
- 历史最高 27.15
- 量 比 0.87
- 振 幅 14.85%
- 历史最低 0.4525
- 每 手 1
- 风险率 0.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gossamer Bio Enters Merger Agreement with Respira
An announcement from Gossamer Bio ( ($GOSS) ) is now available. On September 24...
09-25 21:18
Cantor Fitzgerald Reiterates Overweight on Gossamer Bioto Overweight
Cantor Fitzgerald analyst Olivia Brayer reiterates Gossamer Bio (NASDAQ:GOSS) from Overweight to Overweight.
09-11 20:32
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
UBS Upgrades Gossamer Bio to Buy, Raises Price Target to $9
UBS analyst Eliana Merle upgrades Gossamer Bio (NASDAQ:GOSS) from Neutral to Buy and raises the price target from $1.25 to $9.
09-10 18:44
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
Gossamer shares are trading lower. The company reported Q2 financial results.
Gossamer shares are trading lower. The company reported Q2 financial results.
08-07 00:57
Wedbush Maintains Outperform on Gossamer Bio, Raises Price Target to $5
Wedbush analyst Laura Chico maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and raises the price target from $4 to $5.
08-06 23:59
Gossamer Bio Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $11.49M Beat $4.34M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.03 percent. This is a 177.27 percent decrease over earnings of $0.22 per share from the
08-06 04:24
期权扫描丨SoFi绩后大涨，遭多笔看跌期权押注；联合健康绩后期权成交量暴增
SoFi绩后大涨，遭多笔看跌期权押注；联合健康绩后跌超7%，期权成交量暴增；AMD隔夜涨2.18%，多笔看跌期权大单成交超5万张>>
07-30 19:38
Scotiabank Initiates Coverage On Gossamer Bio with Sector Outperform Rating, Announces Price Target of $11
Scotiabank analyst Greg Harrison initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Sector Outperform rating and announces Price Target of $11.
07-14 19:53
